Hawaii Medical Service Association (HMSA) Prior Authorization Lookup
- Hawaii Medical Service Association (HMSA) coverage criteria
- Hawaii Medical Service Association (HMSA) contact directory
- All Hawaii Medical Service Association (HMSA) policy updates
Latest Hawaii Medical Service Association (HMSA) prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Denosumab Products for Osteoporosis and Cancer-Treatment-Related Bone LossThis policy governs HMSA Medicare Advantage coverage and prior authorization for Prolia and specified denosumab biosimilar products. It defines covered indications, preferred-product exception criteria, authorization durations, continuation requirements, and dosing controls.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Prolia (denosumab) and Denosumab BiosimilarsCoverage and prior authorization for Prolia and denosumab biosimilar products used for osteoporosis, prevention of osteoporosis, glucocorticoid-induced osteoporosis, and treatment-related bone loss associated with prostate or breast cancer therapy for HMSA Medicare Advantage members.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-23Pharmacy Global OncologyThis policy governs precertification and coverage of pharmacy-benefit oncology drugs and medical injectable or infusible drugs prescribed as part of an oncology regimen. The entire regimen may be covered when each drug meets the policy criteria and the member has no applicable exclusions.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Adbry (tralokinumab-ldrm) Coverage CriteriaThis policy governs HMSA commercial coverage and prior authorization for Adbry in members aged 12 years and older with moderate-to-severe atopic dermatitis. It defines clinical criteria, documentation, prescriber qualifications, continuation requirements, and authorization durations.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Cibinqo (abrocitinib) Coverage Criteria for Atopic DermatitisThis policy governs HMSA prior authorization and reauthorization for Cibinqo in members 12 years of age and older with refractory, moderate-to-severe atopic dermatitis. It defines required documentation, prescriber qualifications, clinical criteria, safety requirements, and authorization durations.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Dupixent (dupilumab) Coverage and Prior AuthorizationThis policy governs HMSA coverage and authorization requirements for Dupixent (dupilumab) for specified FDA-approved and compendial indications. It applies to HMO and PPO members and requires indication-specific clinical criteria, documentation, prescriber qualifications, and continuation requirements.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Dupixent (dupilumab) Coverage and Prior AuthorizationThis policy governs HMSA coverage and prior authorization requirements for Dupixent in FDA-approved and compendial indications for QUEST members, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and immune checkpoint inhibitor-related toxicities.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Ebglyss (lebrikizumab-lbkz) Coverage for Moderate-to-Severe Atopic DermatitisThis policy governs HMSA prior authorization and reauthorization for Ebglyss in HMO and PPO members 12 years of age and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Gazyva (obinutuzumab) Coverage for Active Lupus NephritisThis policy governs HMSA coverage and prior authorization for Gazyva (obinutuzumab) for adults with active lupus nephritis receiving standard therapy across HMO, PPO, and QUEST lines of business.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Nemluvio (nemolizumab-ilto) Coverage CriteriaThis policy governs prior authorization and reauthorization for Nemluvio for adult prurigo nodularis and moderate-to-severe atopic dermatitis in members aged 12 years and older. It applies to HMSA QUEST members and requires clinical documentation, specialty prescribing or consultation, and satisfaction of indication-specific criteria.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-07-01Nemluvio (nemolizumab-ilto) Coverage CriteriaThis policy governs HMSA prior authorization and coverage criteria for Nemluvio for adult prurigo nodularis and moderate-to-severe atopic dermatitis in members age 12 and older. It applies to HMO and PPO members and requires documentation, qualifying prior therapy or clinical circumstances, and specialty prescribing.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Bimzelx (bimekizumab-bkzx) Coverage CriteriaHMSA coverage and prior authorization criteria for Bimzelx in adults with specified inflammatory dermatologic and rheumatologic conditions.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Hyaluronate ProductsHMSA coverage and prior authorization for intra-articular hyaluronate products used to treat knee osteoarthritis pain across HMO, PPO, and QUEST lines of business.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Ilaris (canakinumab) Coverage and Prior AuthorizationThis policy governs HMSA Medicare Advantage coverage and precertification for Ilaris (canakinumab) used for specified autoinflammatory diseases, Still's disease, and gout flares. Coverage requires approval criteria for initial therapy, and reauthorization requires ongoing treatment benefit.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Intravenous Immune Globulin (IVIG)This policy governs HMSA Medicare Advantage coverage and precertification requirements for specified intravenous immune globulin products and covered clinical uses. Coverage is available when the applicable indication-specific criteria are met and the member has no exclusions to the prescribed therapy.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Krystexxa (pegloticase) Coverage CriteriaHMSA Medicare Advantage coverage and prior authorization for Krystexxa in adults with chronic gout refractory to conventional therapy, including initial and continuation requirements.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Krystexxa (pegloticase) Coverage for Chronic GoutHMSA coverage and prior authorization for Krystexxa in adults with chronic gout refractory to conventional therapy, including required clinical, documentation, and methotrexate-related criteria.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Mozobil (plerixafor) CoverageThis policy governs HMSA coverage and prior authorization for plerixafor used to mobilize hematopoietic stem cells for collection and subsequent transplantation or gene therapy protocols. It applies to members in the HMO, PPO, and QUEST lines of business when the coverage criteria and applicable benefit requirements are met.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Ocrevus and Ocrevus Zunovo (ocrelizumab) Coverage CriteriaThis policy governs HMSA prior authorization and coverage of Ocrevus and Ocrevus Zunovo for members with specified forms of multiple sclerosis. Coverage requires applicable clinical criteria, prescribing by or consultation with a neurologist, and compliance with other policy requirements.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26VPRIV (velaglucerase)This policy governs HMSA Medicare Advantage coverage and prior authorization for VPRIV (velaglucerase) enzyme replacement therapy in members with Gaucher disease. Coverage applies when applicable diagnosis and confirmation requirements are met and no therapy exclusions apply.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-26Vimizim (elosulfase alfa) Coverage CriteriaThis policy governs HMSA Medicare Advantage coverage and precertification for Vimizim (elosulfase alfa) used to treat Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome), including initial authorization and reauthorization.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-12Global OncologyThis policy governs precertification and coverage of oncology drugs prescribed as single agents or regimens under the medical benefit, including oral drugs used as part of an oncology regimen. It applies to HMSA HMO, PPO, QUEST, and Medicare Advantage members, subject to member contract exclusions and applicable Medicare coverage rules.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-01Flolan, Veletri, and Epoprostenol Injection Coverage CriteriaThis policy governs prior authorization and coverage of epoprostenol products for pulmonary arterial hypertension. It applies to eligible HMSA HMO, PPO, and QUEST members when the clinical and documentation criteria are met.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-01Remodulin (treprostinil) injection coverageThis policy governs HMSA coverage and prior authorization for Remodulin (treprostinil) injection for pulmonary arterial hypertension. It applies to members in the HMO, PPO, and QUEST lines of business when coverage criteria and documentation requirements are met.All Hawaii Medical Service Association (HMSA) updates
- Prior AuthClinical/Medical PolicyEff. 2026-06-01Skyrizi IV (risankizumab-rzaa) CoverageThis policy governs HMSA Medicare Advantage coverage and prior authorization for physician-administered Skyrizi IV used for moderately to severely active Crohn's disease or ulcerative colitis in adults. It excludes indications where Skyrizi is usually self-administered and directs Part D members to seek coverage through their Medicare Part D plan.All Hawaii Medical Service Association (HMSA) updates
Tool Description
Search Hawaii Medical Service Association (HMSA)prior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.